Stock BMYB34 BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Share Price Sao Paulo

Equities

BMYB34

BRBMYBBDR000

Pharmaceuticals

Delayed Sao Paulo
Other stock markets
 06:30:00 31/05/2024 pm IST 		5-day change 1st Jan Change
210 BRL -0.24% Intraday chart for Bristol-Myers Squibb Company -1.73% -15.97%
02:58pm Bristol Myers: presents advances in lung cancer CF
02/06 Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes RE

Financials

Sales 2024 * 4.61TCr 24TCr 3,82800Cr Sales 2025 * 4.61TCr 24TCr 3,82600Cr Capitalization 8.33TCr 44TCr 6,91900Cr
Net income 2024 * -541.4Cr -2.83TCr -45TCr Net income 2025 * 1.02TCr 5.35TCr 85TCr EV / Sales 2024 * 2.65 x
Net Debt 2024 * 3.9TCr 20TCr 3,24200Cr Net Debt 2025 * 3.17TCr 17TCr 2,63100Cr EV / Sales 2025 * 2.5 x
P/E ratio 2024 *
-15.6 x
P/E ratio 2025 *
7.77 x
Employees 34,100
Yield 2024 *
5.86%
Yield 2025 *
6.15%
Free-Float 69.27%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Bristol Myers: presents advances in lung cancer CF
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes RE
GSK blood cancer drug nearly halves risk of death in late-stage trial RE
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®? CI
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma MT
Bristol Myers: FDA approval for Breyanzi CF
US FDA allows use of Bristol's cell therapy for rare blood cancer RE
U.S. Food and Drug Administration Approves Bristol Myers Squibb?s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma CI
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer MT
Bristol Myers: new EC approval for Opdivo CF
Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination with Cisplatin and Gemcitabine CI
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License MT
Bristol Myers: will present data on schizophrenia CF
Bristol Myers: presents over 130 studies at ASCO CF
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting BU
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer BU
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer BU
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma BU
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : présente ses avancées en cancer du poumon
Bristol Myers : approbation de la FDA pour Breyanzi
Bristol Myers : nouvelle approbation de la CE pour Opdivo
Bristol Myers : présentera des données sur la schizophrénie
Bristol Myers : présente plus de 130 études à l'ASCO
More news

Quotes and Performance

1 day-0.24%
1 week-1.73%
1 month-6.07%
3 months-16.58%
6 months-12.06%
Current year-15.97%
More quotes

Highs and lows

1 week
208.00
Extreme 208
212.73
1 month
208.00
Extreme 208
232.99
Current year
208.00
Extreme 208
270.81
1 year
208.00
Extreme 208
325.60
3 years
208.00
Extreme 208
431.76
5 years
160.29
Extreme 160.29
431.76
10 years
111.23
Extreme 111.23
431.76
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 01/15/01
David Elkins DFI
 Director of Finance/CFO 55 20/19/20
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 20/19/20
Peter Arduini BRD
 Director/Board Member 59 01/16/01
Derica Rice BRD
 Director/Board Member 59 01/20/01
More insiders

Quotes

Date Price Change Volume
31/24/31 210 -0.24% 14
29/24/29 210.5 +0.63% 10
28/24/28 209.2 -2.12% 15
27/24/27 213.7 +0.00% 2

Delayed Quote Sao Paulo, May 31, 2024 at 06:30 pm IST

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
06:30pm - American Society of Clinical Oncology Meeting - Abstract No #4507
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09 USD
Average target price
53.19 USD
Spread / Average Target
+29.46%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.64% 74TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.34% 60TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.73% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.33% 32TCr
ABBVIE INC. Stock AbbVie Inc.
+3.44% 28TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.47% 24TCr
NOVARTIS AG Stock Novartis AG
+9.26% 21TCr
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 21TCr
AMGEN INC. Stock Amgen Inc.
+6.09% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMYB34 Stock